Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

LianBio Completes $325 Million US IPO to Support China In-Licensing Program

publication date: Nov 2, 2021

LianBio, a Princeton-Shanghai company, raised $325 million in its NASDAQ IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. LianBio was formed by Perceptive Advisors as a way for the US company to participate in China's market. It has access to the China rights for Perceptive's portfolio of life science companies, though it doesn't have a lock on those rights. Perceptive seeded the company originally, which then raised $310 million from outside investors soon after breaking out of stealth mode one year ago. More details....

Stock Symbol: (NSDQ: LIAN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.